Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2019 07:30 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia

~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...
February 20, 2018 07:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina

NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
March 02, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
January 06, 2016 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia

New Haven, CT, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat bacterial infections, announced the initiation of an...
June 02, 2015 07:30 ET | Source: Melinta Therapeutics

Melinta Therapeutics Joins White House Forum on Antibiotic Stewardship in Commitment to Take Steps to Avert Potential Crisis

New Haven, CT, June 2, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today it is joining with more than 150 other major food companies, retailers, and human and animal health stakeholders at...
May 19, 2015 16:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections

New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative impact of obesity on patients' recovery from acute bacterial skin and skin structure...
April 09, 2015 12:02 ET | Source: Melinta Therapeutics

Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment

New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of Health-Related Quality-of-Life (HRQL) in acute bacterial skin and skin structure infection...
February 09, 2015 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital

New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth...
January 08, 2015 15:08 ET | Source: Melinta Therapeutics

Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil

NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil, announced that...
September 08, 2014 11:01 ET | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae

NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results from in vitro studies that highlight the potential of delafloxacin, an investigational fluoroquinolone,...

Next Page keyboard_arrow_right